-

VectorY Announces Participation in Scientific Conferences in October 2022

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.

5th Annual ALS Research Symposium (ALS ONE), 6-7 & 11 October, virtually

  • Presentation title: Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VecTabs in an Amyotrophic Lateral Sclerosis pre-clinical models
    Presenter: Pavlina Konstantinova, Chief Scientific Officer
    Time and date: October 7, 14:05 ET

European Society of Gene & Cell Therapy (ESGCT) Annual Congress, 11-14 October, Edinburgh

  • Poster title: VecTrons: Targeting misfolded proteins in neurodegenerative diseases
    Presenter: Menno Spits, Scientist
    Poster number: P251
    Time and date: October 12, Poster Session 1,19:30-21:00 BST
  • Poster title: Generation and characterization of stable recombinant baculoviruses for large-scale production of rAAV
    Presenter: Hilde van Tongeren, Head of Vector Generation
    Poster number: P293
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST
  • Poster title: VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic lateral sclerosis
    Presenter: Andreia Duarte, Scientist
    Poster number: P353
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST
  • Poster title: Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases
    Presenter: Carmen Gallego, Scientist, Vector Technologies
    Poster number: P056
    Time and date: October 13, Poster Session 2, 17:30-19:15 BST

2022 Cell & Gene Meeting on the Mesa, 11-13 October, Carlsbad, CA

  • Presentation title: Precision targeted gene therapies for CNS and neuromuscular disease
    Presenter: Barbara Sanders, Chief Technology Officer
    Time and date: October 13, 11:45 PT

To meet the VectorY team at any of these meetings, please contact info@vectorytx.com.

ENDS

Notes to Editors

About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and muscular diseases with high unmet medical need such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and muscular diseases, VectorY's synergistic technologies may be applied across a wide range of indications.

VectoryY was founded in October 2020 and is based on the Amsterdam Science Park.

For more information, see www.vectorytx.com.

Contacts

VectorY B.V.
Sariette Witte, Head of Communications
Email: sariette.witte@vectorytx.com
Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

Industry:

VectorY Therapeutics

Release Versions
English

Contacts

VectorY B.V.
Sariette Witte, Head of Communications
Email: sariette.witte@vectorytx.com
Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

More News From VectorY Therapeutics

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. VTx-002 is a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). TDP-43 pathology drives up to 97 percent of ALS cases. VTx-002, VectorY’s lead vectorized antibody pro...

VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Adam Rosenberg as the new Chair of the Board. Boston-based Mr Rosenberg brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space. He replaces Dr Carlo Incerti who is stepping down from the company’s board. The appointment comes at a pivot...

UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study

UTRECHT, Netherlands & AMSTERDAM--(BUSINESS WIRE)--UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics. VectorY Therapeutics is developing innovative vectorized antibody therapies for neurodegenerative diseases. VectorY’s lead program, VTx-002, is targeting TDP-43 for the treatment of ALS. ALS is a...
Back to Newsroom